Shares of Axovant Sciences Ltd. (NYSE:AXON) have earned an average recommendation of “Buy” from the twelve research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $28.69.

Several analysts recently issued reports on the stock. Jefferies Group LLC restated a “buy” rating and issued a $31.00 price objective on shares of Axovant Sciences in a report on Friday. CIBC boosted their price target on shares of Axovant Sciences from $30.00 to $33.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 18th. Oppenheimer Holdings, Inc. boosted their price target on shares of Axovant Sciences from $30.00 to $33.00 and gave the stock a “neutral” rating in a research note on Monday, April 17th. Piper Jaffray Companies reiterated an “overweight” rating and set a $32.00 price target on shares of Axovant Sciences in a research note on Wednesday, April 12th. Finally, Zacks Investment Research upgraded shares of Axovant Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, March 9th.

Axovant Sciences (NYSE AXON) opened at 21.67 on Tuesday. Axovant Sciences has a one year low of $11.01 and a one year high of $25.18. The company’s market capitalization is $2.15 billion. The firm’s 50-day moving average is $22.73 and its 200 day moving average is $16.19.

TRADEMARK VIOLATION NOTICE: “Axovant Sciences Ltd. (AXON) Given Average Rating of “Buy” by Brokerages” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/06/13/axovant-sciences-ltd-axon-given-average-rating-of-buy-by-brokerages.html.

In related news, Director W Anthony Vernon acquired 53,937 shares of the stock in a transaction dated Monday, April 17th. The stock was acquired at an average cost of $18.54 per share, with a total value of $999,991.98. Following the completion of the transaction, the director now owns 53,937 shares in the company, valued at approximately $999,991.98. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David Hung acquired 539,375 shares of the stock in a transaction dated Monday, April 17th. The shares were bought at an average cost of $18.54 per share, with a total value of $10,000,012.50. Following the completion of the transaction, the insider now owns 539,375 shares of the company’s stock, valued at approximately $10,000,012.50. The disclosure for this purchase can be found here. 3.10% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE increased its position in shares of Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,072 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Axovant Sciences during the fourth quarter worth approximately $139,000. Oppenheimer & Co. Inc. bought a new position in shares of Axovant Sciences during the first quarter worth approximately $219,000. American International Group Inc. increased its position in shares of Axovant Sciences by 7.1% in the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after buying an additional 998 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Axovant Sciences by 34.3% in the first quarter. Wells Fargo & Company MN now owns 22,435 shares of the biotechnology company’s stock worth $335,000 after buying an additional 5,733 shares in the last quarter.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.